REP1 Gene Replacement Therapy for Choroideremia

Summary

REP1 Gene Replacement Therapy for Choroideremia is a clinical trial^[1].

Key Facts

• REP1 Gene Replacement Therapy for Choroideremia is in the country of United Kingdom^[2].
• REP1 Gene Replacement Therapy for Choroideremia's instance of is recorded as clinical trial^[3].
• REP1 Gene Replacement Therapy for Choroideremia's start time is recorded as +2016-08-31T00:00:00Z^[4].
• REP1 Gene Replacement Therapy for Choroideremia's end time is recorded as +2019-08-31T00:00:00Z^[5].
• REP1 Gene Replacement Therapy for Choroideremia's contributor to the creative work or subject is recorded as Moorfields Eye Hospital^[6].
• REP1 Gene Replacement Therapy for Choroideremia's main subject is recorded as choroideremia^[7].
• REP1 Gene Replacement Therapy for Choroideremia's number of participants is recorded as {'unit': '1', 'amount': '+30'}^[8].
• REP1 Gene Replacement Therapy for Choroideremia's title is recorded as An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)^[9].
• REP1 Gene Replacement Therapy for Choroideremia's short name is recorded as REGENERATE^[10].
• REP1 Gene Replacement Therapy for Choroideremia's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
• REP1 Gene Replacement Therapy for Choroideremia's ClinicalTrials.gov ID is recorded as NCT02407678^[12].
• REP1 Gene Replacement Therapy for Choroideremia's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+90'}^[13].
• REP1 Gene Replacement Therapy for Choroideremia's clinical trial phase is recorded as phase II clinical trial^[14].
• REP1 Gene Replacement Therapy for Choroideremia's research site is recorded as Moorfields Eye Hospital NHS Foundation Trust^[15].
• REP1 Gene Replacement Therapy for Choroideremia's study type is recorded as interventional study^[16].